Japan Anemia Market Insight
Published: 27 May 2026 | Report Format: Electronic (PDF)
Japan is witnessing growth at a CAGR of 5.48% on account of an increase in patient population suffering from iron deficiency anemia, chronic kidney diseases, and high demand for advanced hematology devices.
Japan Anemia Market Insights Forecasts to 2035
- The Japan Anemia Market Size Was Estimated at USD 1.32 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.48 % from 2025 to 2035
- The Japan Anemia Market Size is Expected to Reach USD 2.25 Billion by 2035
Notable Insights for Japan Anemia Market
- Regarding the anemia type, the iron deficiency anemia represented around 48-50% of the Japan anemia market share in 2025 because of the rising incidence of nutritional deficiencies, aged population, and chronic diseases.
- With respect to the treatment type, ESAs contributed about 34-36% of the Japan anemia market share in 2025 because of their increased usage in the treatment of anemia associated with chronic kidney disease and chemotherapeutic anemia.
- The grwing prevalence of patients with cancer, chronic kidney diseases, hematological disorders, and aging population in Japan is creating a need for advanced diagnostic tests and treatment procedures within the Japan anemia market.
- The growing capital investments in AI-driven hematology analyzers, oral/parenteral iron medications, precision medicine technologies, and point-of-care diagnostic solutions will generate lucrative growth opportunities for Japan market players.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Advanced Hematology Assessment and Chronic Disease Trend Analysis
Decisions Advisors provides detailed analysis of anemia therapeutics, hematology diagnostics, ESA therapies, and iron supplementation technologies influencing the Japan anemia industry.
- Advanced Healthcare Forecasting and Hematology Evaluation Framework
Our research methodology integrates expert interviews, pharmaceutical benchmarking, clinical treatment analysis, and proprietary forecasting models to deliver accurate market intelligence for Japan’s evolving anemia sector.
- AI-Driven Healthcare Competition and Hematology Opportunity Mapping
We evaluate competitive positioning, anemia diagnostic advancements, iron therapy developments, supportive care innovations, and intelligent healthcare technologies shaping investment opportunities across the Japan anemia market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Anemia market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment Market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the Market.
Top Companies in Japan Anemia Market
- Amgen Inc.
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Vifor Pharma Management Ltd
- Akebia Therapeutics, Inc.
- Janssen Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Other
Recent Developments:
- In April 2026, pharmaceutical companies accelerated investments in long-acting erythropoiesis-stimulating agents and advanced oral iron formulations to improve anemia treatment outcomes and patient compliance.
Market Segmentation:
Japan Anemia Market, By AnemiaType
- Iron Deficiency Anemia
- Aplastic Anemia
- Hemolytic Anemia
- Sickle Cell Anemia
- Chemotherapy-Induced Anemia
- Others
Japan Anemia Market, By Treatment Type
- Oral Iron Therapy
- Parenteral Iron Therapy
- Erythropoiesis-Stimulating Agents (ESAs)
- Red Blood Cell Transfusion
- Others
Japan Anemia Market, By End User
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Ambulatory Care Centers
- Home Healthcare Settings
- Others
Expert Views:
The Japan anemia market is projected to see quite significant growth in the next years, mainly because chronic disease prevalence is keep rising, the aging population is expanding. Also, investments in advanced hematology technologies are increasing too. In the Japan market, progress in AI-powered diagnostics, therapies that stimulate erythropoiesis, precision hematology platforms, and smart patient monitoring systems are expected to be a real engine for demand. On top of that, more funding for personalized medicine ecosystems, supportive care technologies, and improved healthcare infrastructure should open up plenty of growth pathways for companies working in the Japan anemia industry.
Author: Komal and Radhika By Spherical Insights and Consulting